• Patient Site
  • V-Go Customer Care
vgo green
  • Call 1-866-881-1209
  • About V-Go
    • What is V-Go®?
    • Who is it For?
    • How it Works
    • Why V-Go®?
    • Authorized Distributors
  • Clinical Data
    • Optimize Delivery
    • Efficacy
    • Insulin Reduction
    • Patient Adherence
  • Prescribing & Dosing
    • Overview
  • Patient Support
    • Starting Patients
    • Comprehensive Support for You and Your Patients
    • Common Patient Questions
  • Coverage & Savings
    • Overview
  • Pharmacists
    • Overview
    • Reimbursement Card
Two doctors speaking

Reduce the Daily Struggle of Adherence to MDI with V-Go®

Graph showing average A1c reduction in patients after switching to V-Go

Change the Delivery.
Improve the Results.

Patients who switched to V-Go experienced a drop in A1c—which reversed when patients discontinued V-Go.1

Observational trial of 31 patients with diabetes mellitus previously treated with insulin pens or syringes switched to V-Go to obtain patient feedback on the patient instructions and functionality of the V-Go. For 23 patients, physicians retrospectively collected clinical data for analysis; data were collected at baseline, 12 weeks after V-Go initiation, at the end of V-Go use, and 12 weeks after the end of V-Go use.1

Effective Delivery. Powerful Outcomes.

V-Go’s innovative insulin delivery has demonstrated significant reductions in A1c and insulin requirements compared with multiple daily injections (MDI).7

Rates of hypoglycemia did not differ from baseline over 27 weeks of V-Go therapy.2

Graphic depicting A1c and insulin decrease after switching to V-Go

*This value was calculated by averaging the mean upper (117) and mean lower (102) prescribed TDD. Reduction in A1c (P<0.0001) compared to baseline. Reduction in TDD (P<0.0001) compared to baseline. Prior to V-Go initiation, patients had a mean A1c of 9.4%. Based on real-world, retrospective database analysis of an electronic medical record database. Patients were adults diagnosed with diabetes mellitus, A1c ≥7%, and previously prescribed basal-bolus insulin therapy. A total of 86 patients were evaluated.

References:
1. Rosenfeld CR, Bohannon NJ, Bode B, et al. The V-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract. 2012;18(5):660-667. 2. Lajara R, Fetchick DA, Morris TL, Nikkel C. Use of V-Go Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System. Diabetes Ther. 2015;6(4):531-545. 7. Lajara R, Nikkel C. Poster presented at: American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress; May 13-17, 2015; Nashville, TN. Poster 273T.

Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.

  • Product Specs
  • Important Safety Information
  • Contact Us
  • Zealand Pharma
  • Terms of Use & Privacy
  • Cookies
  • Site Map
  • Twitter
  • YouTube
Zealand Pharma Logo Neg (Mar2020) 316x116
White V-Go® logo
© 2021 Zealand Pharma A/S
This website uses cookies to improve your browsing experience. Read MoreAccept
Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT